Embolic Protection Devices Market: Worldwide Industry Analysis and New Opportunities Explored

According to the new market research report "Embolic Protection Devices Market by Type (Distal Filter, Distal Occlusion, Proximal Occlusion), Material (Nitinol, Polyurethane), Application (Cardiovascular, Neurovascular, Peripheral), Indication (PCI, SVD, TAVR) - Global Forecast to 2023", published by MarketsandMarkets™, the global embolic protection devices market is projected to reach USD 604.9 Million by 2023 from USD 405.5 Million in 2018, at a CAGR of 8.3% during the forecast period.

The growth in this market is mainly attributed to factors such as the rising incidence of cardiovascular and neurovascular diseases, growing funding and investments, launch of technologically advanced embolic protection devices, and the rising demand for minimally invasive procedures.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158143803

By application, the neurovascular segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, the market is categorized into cardiovascular, neurovascular, and peripheral vascular diseases. The neurovascular segment is expected to grow at the highest CAGR during the forecast period. The favorable medical reimbursement scenarios for neurovascular procedures in developed countries, increasing awareness about the clinical efficacy of embolic protection devices among neurosurgeons, and the rising adoption of these systems across developing countries (such as China and India) are expected to drive the growth of this application segment during the forecast period.

Browse and in-depth TOC on "Embolic Protection Devices Market"

127 - Tables

28 - Figures

172 - Pages

By indication, the percutaneous coronary intervention segment accounted for the largest market share in 2017

On the basis of indication, the market is categorized into percutaneous coronary intervention, transcatheter aortic valve replacement (TAVR), carotid artery diseases, saphenous vein graft disease, and other indications. In 2017, the percutaneous coronary intervention segment accounted for the largest share of the global embolic protection devices market. The large share of this segment can primarily be attributed to the increasing prevalence of CAD and the rising preference for minimally invasive procedures.

Hospitals are expected to be the largest end users of embolic protection devices during the forecast period

The major end users of embolic protection devices market are hospitals and ambulatory surgical centers. The hospital segment is expected to grow at the highest CAGR during the forecast period. The market for this segment is mainly driven by factors such as the growing number of angioplasty procedures performed in hospitals, rising incidence of chronic vascular diseases, favorable reimbursement scenario in developed countries, growing number of hospitals, and increasing government initiatives to provide quality treatment for cardiovascular diseases.

Request Research Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=158143803

North America dominated the market in 2017, and APAC is expected to grow at the highest CAGR

In 2017, North America dominated the embolic protection devices market. The rising geriatric population and prevalence of cardiovascular and neurovascular diseases, increasing adoption of minimally invasive techniques, increasing availability of funding, and the presence of a large number of medical device product manufacturers are driving the growth of the embolic protection devices market in North America. However, the APAC is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to the growing geriatric population, rising prevalence of CVD, increasing number of facilities, and rising healthcare expenditure.

The prominent players in the embolic protection devices market are Boston Scientific (US), Medtronic (Ireland), Abbott (US), Cordis (A Cardinal Health Company) (US), Allium Medical (Israel), Contego Medical (US), W.L. Gore & Associates (US), Silk Road Medical (US), Claret Medical (US), and AngioSlide (Israel).

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

Email: sales@marketsandmarkets.com

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 com